Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$35.30 USD

35.30
95,229

+0.27 (0.77%)

Updated Aug 7, 2025 12:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hill-Rom Adds New Capabilities to Centrella Smart+ Beds

by Zacks Equity Research

Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.

Zacks Equity Research

Varian Medical ProBeam-Equipped Emory Center Opens in Georgia

by Zacks Equity Research

Varian Medical's (VAR) flagship ProBeam system has lucrative prospects.

Zacks Equity Research

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Myriad Genetics (MYGN) see strong testing volumes from new products.

Zacks Equity Research

Baxter & EFCNI Collaborate to Improve Care for Preterm Born

by Zacks Equity Research

Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.

Zacks Equity Research

Here's Why You Should Invest in athenahealth (ATHN) Now

by Zacks Equity Research

A strong guidance and focus on big data-based health records system make athenahealth (ATHN) a solid investment pick.

Zacks Equity Research

Illumina (ILMN) Takes Part in NIH Program With Genotype Launch

by Zacks Equity Research

The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

A strong international presence and strategic buyouts aid Varian Medical (VAR); margins pressed.

Zacks Equity Research

Quest Diagnostics Rides on Product Launches, Strategic Deals

by Zacks Equity Research

Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.

Zacks Equity Research

STERIS (STE) Dips on New Restructuring Plan, Layoff Decision

by Zacks Equity Research

STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.

Zacks Equity Research

Here's Why You Should Invest in Veeva Systems (VEEV) Now

by Zacks Equity Research

A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.

Zacks Equity Research

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

by Zacks Equity Research

Chemed's (CHE) subsidiaries continue to register strong sales.

Zacks Equity Research

ResMed to Buy Propeller Health, Widens Respiratory Care Suite

by Zacks Equity Research

Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.

Zacks Equity Research

Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds

by Zacks Equity Research

Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.

Zacks Equity Research

Genomic Health (GHDX), BioCartis Extend Deal to Urology

by Zacks Equity Research

The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.

Zacks Equity Research

Zimmer Biomet Rides on New Operational Plan Amid Several Woes

by Zacks Equity Research

In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.

Zacks Equity Research

LabCorp (LH) Stock Declines 10% on Lowered 2018 Guidance

by Zacks Equity Research

Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.

Zacks Equity Research

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

by Zacks Equity Research

Omnicell (OMCL) continues to witness strong conversion wins for new XT series.

Zacks Equity Research

CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing

by Zacks Equity Research

The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.

Zacks Equity Research

QIAGEN's New Offerings to Broaden Hematology Testing Suite

by Zacks Equity Research

QIAGEN (QGEN) continues to progress with test menu expansion.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Right Now

by Zacks Equity Research

A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.

Zacks Equity Research

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.

Zacks Equity Research

Varian Medical's (VAR) Halcyon Gets NMPA Approval in China

by Zacks Equity Research

Varian Medical (VAR) enjoys significant international presence in radiotherapy.

Zacks Equity Research

Walgreens Gains from New Alliances, International Expansion

by Zacks Equity Research

Walgreens Boots (WBA) is benefiting from strategic tie-ups. The Express Scripts and Kroger deals are intended to expand its existing group purchasing efforts and product offerings.

Zacks Equity Research

Integra's (IART) Margin Pressure Hurts, Global Prospects High

by Zacks Equity Research

Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).

Zacks Equity Research

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.